Sandbox g16: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) |
Gerald Chi- (talk | contribs) mNo edit summary |
||
| Line 20: | Line 20: | ||
* Mild hepatic impairment (Child-Pugh class A): 400 mg once daily | * Mild hepatic impairment (Child-Pugh class A): 400 mg once daily | ||
* Moderate hepatic impairment (Child-Pugh class B): 300 mg once daily | * Moderate hepatic impairment (Child-Pugh class B): 300 mg once daily | ||
* Severe hepatic impairment (Child-Pugh class C): not recommended | * Severe hepatic impairment (Child-Pugh class C): not recommended | ||
|- | |- | ||
| Caspofungin | | Caspofungin | ||
Revision as of 03:33, 4 June 2015
Dosage adjustment in patients with hepatic disease Return to Top
Dosage adjustment may be required in the presence of hepatic disease for the following medications (consult FDA package insert for details):
| Antimicrobial Agent | Category | Recommendation |
|---|---|---|
| Abacavir | Antiviral agent |
|
| Atazanavir | Antiviral agent |
|
| Caspofungin | ||
| Ceftriaxone | ||
| Chloramphenicol | ||
| Clindamycin | ||
| Darunavir | ||
| Delavirdine | ||
| Efavirenz | ||
| Enfuvirtide | ||
| Fosamprenavir | ||
| Fusidic acid | ||
| Indinavir | ||
| Isoniazid | ||
| Itraconazole | ||
| Lopinavir-Ritonavir | ||
| Metronidazole | ||
| Nafcillin | ||
| Nelfinavir | ||
| Nevirapine | ||
| Quinupristin-Dalfopristin | ||
| Rifabutin | ||
| Rifampin | ||
| Rimantadine | ||
| Ritonavir | ||
| Telithromycin | ||
| Tigecycline | ||
| Tinidazole | ||
| Voriconazole |